businesspress24.com - BioSyent Announces Sale of Shares
 

BioSyent Announces Sale of Shares

ID: 1475224

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 12/12/16 -- BioSyent Inc. ("BioSyent", "the company") (TSX VENTURE: RX) President & CEO Rene Goehrum has advised the company that he has sold 300,000 shares in a single block to an existing institutional shareholder of BioSyent in a non-open market transaction. Mr. Goehrum continues to be the largest shareholder of BioSyent, holding a total of 2,245,261 BioSyent shares either directly or indirectly.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,401,087 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.



Contacts:
Mr. Rene C. Goehrum
President and CEO
BioSyent Inc.
(905) 206-0013





Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Proove Biosciences Launches Version 2.0 of Its One-Of-A-Kind Proove Pain Perception Profile
OrganiGram Reports Financial Results and Summary Update
Bereitgestellt von Benutzer: Marketwired
Datum: 12.12.2016 - 18:00 Uhr
Sprache: Deutsch
News-ID 1475224
Anzahl Zeichen: 2216

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Alternative


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 240 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"BioSyent Announces Sale of Shares
"
steht unter der journalistisch-redaktionellen Verantwortung von

BioSyent Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von BioSyent Inc.



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 155


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.